Welcome to our dedicated page for VERACYTE SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Veracyte, Inc. filings document the regulatory record for a Nasdaq-listed cancer diagnostics company with a portfolio that includes Decipher, Afirma, Prosigna, and bladder cancer diagnostics. The company’s Form 8-K reports primarily cover operating and financial results, preliminary financial and testing-volume estimates, and material corporate events.
Veracyte’s proxy and governance filings disclose shareholder voting matters, board and executive compensation practices, equity award information, and governance procedures. Other material-event filings address officer appointments, compensatory arrangements, capital-structure disclosures, and formal exhibits tied to financial reporting and corporate actions.
Veracyte (VCYT) reported an insider transaction by its SVP, General Counsel. On 11/05/2025, the officer sold 6,466 shares of common stock at $40 per share, coded as an open market sale (S). Following the sale, the reporting person beneficially owned 82,973 shares, held directly. The filing notes the trades were made pursuant to a Rule 10b5-1 trading plan adopted on September 4, 2024.
Veracyte, Inc. (VCYT) reported an insider transaction by a director. On 11/05/2025, the insider exercised stock options for 30,000 shares at exercise prices of $5.28, $7.94, and $7.60, then sold 43,196 shares in multiple trades at weighted average prices ranging from $41.10 to $46.40. These transactions were made pursuant to a Rule 10b5-1 trading plan adopted on December 9, 2024.
Following the transactions, the insider directly beneficially owns 30,468 shares. The options exercised were fully vested, tied to grants expiring on 06/20/2026, 06/07/2027, and 06/07/2028.
Veracyte, Inc. (VCYT) reported an insider transaction by a director. On 11/05/2025, the reporting person sold 9,674 shares of common stock, coded “S”. The weighted average sale price was $40.0239, with individual trades ranging from $40.00 to $40.70.
Following the sale, the insider beneficially owned 13,554 shares, held directly. The transactions were made under a Rule 10b5-1 trading plan adopted on August 20, 2024, which pre‑sets trading instructions.
Veracyte, Inc. (VCYT) reported an insider transaction on Form 4. The company’s Chief Financial Officer sold 7,000 shares of common stock at $41 on 11/05/2025, marked with transaction code S. The filing notes the trades were made under a Rule 10b5-1 plan adopted on August 13, 2024.
After the sale, the officer beneficially owns 126,158 shares, held directly.
Veracyte, Inc. reported stronger Q3 2025 results, with total revenue of $131.9 million, up from $115.9 million a year ago. Testing revenue rose to $127.8 million, while product revenue was $3.3 million and biopharmaceutical and other revenue was $0.8 million. Gross profit increased to $91.3 million. Net income was $19.1 million versus $15.2 million last year, and diluted EPS was $0.24 versus $0.19.
Operating expenses were $68.3 million. Other income (loss), net was a loss of $4.1 million, reflecting a $6.7 million loss on deconsolidation of the French subsidiary in August 2025. For the nine months, operating cash flow was $83.7 million, up from $50.6 million. The balance sheet showed cash and cash equivalents of $315.6 million, short‑term investments of $50.9 million, and stockholders’ equity of $1.26 billion as of September 30, 2025. Medicare and UnitedHealthcare represented 33% and 14% of Q3 revenue, respectively. Shares outstanding were 79,049,173 as of October 31, 2025.
Veracyte, Inc. furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The results are provided in a press release attached as Exhibit 99.1.
The company states this information, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act, and is not incorporated by reference unless specifically so stated.
Veracyte, Inc. (VCYT) officer Jonathan Wygant, VP and Chief Accounting Officer, reported an equity award on Form 4. On 10/28/2025, he acquired 2,886 shares of common stock at $0 under transaction code A, reflecting a restricted stock unit grant. Following the transaction, his beneficial ownership stands at 49,665 shares, held directly.
The filing notes the RSUs were awarded on October 28, 2025 and vest in full on the first anniversary of the grant date, subject to his continued employment.
Veracyte, Inc. insider Phillip G. Febbo sold 8,349 shares of common stock on 10/06/2025 at a weighted average price of $36.0174, reducing his beneficial ownership to 92,441 shares. The filing states the sales were made under a Rule 10b5-1 trading plan adopted on 09/04/2024, and individual sale prices ranged from $35.82 to $36.28. The Form 4 was signed by an attorney-in-fact on 10/07/2025. No options or derivative transactions were reported.
Veracyte, Inc. notice reports a proposed sale of 8,349 common shares on NASDAQ with an aggregate market value of $300,564. The shares represent restricted stock units acquired from the issuer on 12/02/2024 and were paid/issued on the same date. The filing states there were 78,671,588 shares outstanding, and the seller reports no securities sold in the prior three months. The sale is planned for 10/06/2025. The filer affirms they are not aware of undisclosed material adverse information and signs the notice consistent with Rule 144 requirements.
Veracyte (VCYT) insider transaction: The company’s Chief Commercial Officer-CLIA reported a sale of 2,539 shares of common stock at $35 on 10/01/2025, coded “S”. The filing notes the trades were made under a Rule 10b5-1 plan adopted on June 9, 2025. Following the transaction, the reporting person beneficially owns 89,099 shares, held directly.